Home > Online Clinic News > Belviq Close to US Debut

Latest News

by Robert MacKay, Thursday, May 9, 2013 | Categories: Lorcaserin

The new weight loss drug Belviq© just got a step closer to being available to prescribe in the US. The medication had been approved by the US Food and Drug Administration (FDA) last June: however, Arena Pharmaceuticals was waiting for the Drug Enforcement Administration (DEA) to classify Belviq. Finally, yesterday the drug has been classified as a schedule IV drug (i.e. with low prospective of abuse).

The sale of this medication is therefore scheduled to begin 30 days after publication in the Federal Register, which happened yesterday (8 May 2013).

This medication will be available to overweight and obese individuals to help reduce the body weight, along with a healthy and correct nutrition. The active ingredient of this medication is lorcaserin. The details of how the medication works are still unknown: however what it is known is that the substance activates selectively certain serotonin 2C brain receptors and therefore changes the perception of satiation of the patient. Therefore the individual feels full faster. Side effects of the drug include fatigue, somnolence, impairment of memory and confusion. Therefore patients should be monitored by a doctor especially when starting the first cycle of medication.

We want to highlight that this medication has just been approved in the United States and not in Europe. An application has been filed in the EU but no decision has yet been made.





 
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close